Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 57.1%High 3 · 42.9%

Hormone therapy vs placebo

Venous thromboembolism · Post‐menopausal women without prior cardiovascular disease

Hormone therapy probably leads to higher venous thromboembolism compared with placebo (moderate certainty).

1 finding from 1 review

Hormone therapy for preventing cardiovascular disease in post‐menopausal women 2015 · Cochrane Headline outcomes only
RR 1.92 [1.24, 2.99]
6 studies · 33477 participants
Moderate

Hormone therapy vs placebo

Venous thromboembolism · Post‐menopausal women with pre‐exisiting cardiovascular disease

Hormone therapy leads to higher venous thromboembolism compared with placebo (high certainty).

1 finding from 1 review

Hormone therapy for preventing cardiovascular disease in post‐menopausal women 2015 · Cochrane Headline outcomes only
RR 2.02 [1.13, 3.62]
6 studies · 4399 participants
High

Oestrogen therapy alone vs placebo

Venous thromboembolism · relatively healthy postmenopausal women

Oestrogen‐only hormone therapy (HT) probably leads to higher venous thromboembolism (DVT or PE) compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 2.22 [1.12, 4.39]
1 study · 10739 participants
Moderate

Combined continuous hormone therapy (HT) vs placebo

Venous thromboembolism · relatively healthy postmenopausal women

Combined continuous hormone therapy (HT) probably leads to higher venous thromboembolism (DVT or PE) compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 4.28 [2.49, 7.34]
2 studies · 20993 participants
Moderate

Oestrogen therapy alone vs placebo

Venous thrombo‐embolism (DVT or PE): CEE 0.625 mg (moderate dose) · relatively healthy postmenopausal women

Oestrogen‐only hormone therapy (HT) showed no clear difference in venous thromboembolism (DVT or PE): CEE 0.625 mg (moderate dose) compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term hormone therapy for perimenopausal and postmenopausal women 2017 · Cochrane Headline outcomes only
RR 1.32 [1, 1.74]
1 study · 10739 participants
Moderate

Intervention not reported

Venous thromboembolism · Post‐menopausal women

The intervention leads to higher venous thromboembolism (high certainty).

1 finding from 1 review

Hormone therapy for preventing cardiovascular disease in post‐menopausal women 2015 · Cochrane Headline outcomes only
RR 1.74 [1.11, 2.73]
3 studies · 9838 participants
High

Intervention not reported

Venous thromboembolism · Post‐menopausal women

The intervention leads to higher venous thromboembolism (high certainty).

1 finding from 1 review

Hormone therapy for preventing cardiovascular disease in post‐menopausal women 2015 · Cochrane Headline outcomes only
RR 1.96 [1.37, 2.8]
9 studies · 27475 participants
High